KRAS codon(s) 12 any
KRAS belongs to the RAS family of oncogenes. KRAS mutations have been described in approximately 3–40% gall bladder adenocarcinomas (more often in East Asia). The prognostic and therapeutic implications of KRAS mutations in gall bladder adenocarcinomas continue to be explored.
Javle M et al. Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling. Human pathology. 2014;45(4):701-708. doi:10.1016/j.humpath.2013.11.001.
Disclaimer: You assume full responsibility for all risks associated with using this PMKB website. The IPM makes no guarantee of the comprehensiveness, reliability or accuracy of the information on this website and the IPM assumes no responsibility for errors in the information associated with this web site. Healthcare providers and patients must integrate all clinical and laboratory findings as well as information from a variety of sources before deciding on appropriate clinical care options.